These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28864095)

  • 21. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Cheson BD; Mato AR
    Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?
    Ghia P
    Hematology Am Soc Hematol Educ Program; 2012; 2012():97-104. PubMed ID: 23233566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
    Varghese AM; Howard DR; Pocock C; Rawstron AC; Follows G; McCarthy H; Dearden C; Fegan C; Milligan D; Smith AF; Gregory W; Hillmen P;
    Br J Haematol; 2017 Feb; 176(4):573-582. PubMed ID: 28032335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Michallet AS; Letestu R; Le Garff-Tavernier M; Aanei C; Ticchioni M; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; De Guibert S; Orsini Piocelle F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan-Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Levy V; Nguyen-Khac F; Feugier P
    Blood; 2021 Feb; 137(8):1019-1023. PubMed ID: 33167024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
    Stumpf J; Al-Sawaf O
    Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
    Thompson PA; Peterson CB; Strati P; Jorgensen J; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Kadia TM; Borthakur G; DiNardo CD; Daver N; Jabbour E; Wierda WG
    Leukemia; 2018 Nov; 32(11):2388-2398. PubMed ID: 29769624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
    Al-Sawaf O; Fischer K; Herling CD; Ritgen M; Böttcher S; Bahlo J; Elter T; Stilgenbauer S; Eichhorst BF; Busch R; Elberskirch U; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Eur J Haematol; 2017 Mar; 98(3):254-262. PubMed ID: 27862308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advances in the treatment of chronic lymphocytic leukaemia].
    Mozas P; Delgado J
    Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease assessment in chronic lymphocytic leukaemia.
    Sayala HA; Rawstron AC; Hillmen P
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
    Uchiyama T; Yokoyama A; Aoki S
    J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
    Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.
    Oughton JB; Collett L; Howard DR; Hockaday A; Munir T; McMahon K; McParland L; Dimbleby C; Phillips D; Rawstron AC; Hillmen P
    Trials; 2017 Jul; 18(1):353. PubMed ID: 28747208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
    Al-Sawaf O
    Acta Haematol; 2024; 147(1):22-32. PubMed ID: 37903476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing minimal residual disease in chronic lymphocytic leukemia.
    Rawstron AC; Hillmen P
    Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.